Hepatic veno-occlusive disease (VOD) of the liver is a common complication following high-dose cytotoxic therapy for bone marrow transplantation (BMT). The major pathological changes are seen in centrilobular (zone 3) hepatocytes and adjacent endothelium. Glutathione (GSH) becomes depleted following chemotherapy and experimental evidence suggests reduced levels predispose to centrilobular hepatocyte and endothelial cell injury. Animal studies have shown that glutamine infusions can maintain GSH levels and protect against free radical injury. We have prospectively studied the effect of glutamine supplementation during BMT. Thirty-four patients undergoing BMT were randomised to receive either glycl-L-glutamine (n = 18) or an isonitrogenous mixture of non-essential amino acids (n = 16). Glutamine was shown to significantly preserve protein C (days ؉4 and ؉7, P Ͻ 0.05) and albumin levels (days 0 and ؉4, P Ͻ 0.02). Markers of thrombin and plasmin generation (thrombin-antithrombin, prothrombin fragment F1؉2 and plasmin-antiplasmin levels) were not significantly changed between the two groups. These findings suggest that glutamine preserves hepatic function but does not alter thrombin or plasmin generation during BMT. Previous studies have shown reductions in protein C, albumin, factor X and factor VII levels post BMT. Falling protein C levels have been shown to be predictive of severe VOD. These data suggest a role for glutamine in the protection of hepatic function following BMT.
veins, dilatation and engorgement of sinusoids, closure of sinusoidal fenestrae and necrosis of hepatocytes in zone 3 of the acinus. A mechanism that may result in this pattern of damage is depletion of glutathione (GSH) allowing hepatocyte and/or endothelial cell injury. The centrilobular zone is relatively depleted of GSH and is the site of glutathionedependent detoxifying enzymes. Agents used in conditioning regimens cause GSH depletion, eg BCNU, TBI and busulphan. 4 As GSH is the main antioxidant of the hepatic cytosol this reduces the protection of hepatocytes and endothelial cells from free radicals and activated chemotherapeutic metabolites. 5 Glutamine becomes the rate-limiting factor in hepatocyte production of GSH during periods of catabolic stress. Standard intravenous hyperalimentation regimens do not provide glutamine supplementation, and this amino acid becomes conditionally essential in times of starvation. Because l-glutamine itself is unstable in solution, this has led to the recent development of dipeptides such as glycl-l-glutamine and alanyl-l-glutamine that are stable in solution and are hydrolysed rapidly to l-glutamine. Glutamine supplementation preserves hepatic GSH levels in rats and may potentially be protective against centrilobular damage. 6 We have prospectively studied the effect of glutamine supplementation during BMT on hepatic function, and markers of thrombin and plasmin generation to determine whether glutamine has a protective role.
Patients and methods
Thirty-four patients undergoing BMT were recruited into this double-blinded prospective study (Table 1) . Informed consent was obtained from all patients. The patients were randomised to receive either a daily infusion of 50 g glycll-glutamine (n = 18) or a daily infusion of an isonitrogenous mixture of non-essential amino acids (n = 16) from the start of conditioning until discharge from the BMT unit. Some patients received prophylactic warfarin during conditioning until the platelet count fell below 50 ϫ 10 9 /l because of prior Hickman line thrombosis or to prevent this complication (1 mg daily, see Table 1 ). Some patients received vitamin K (10 mg i.v. weekly) either singly or after cessation of warfarin for coagulopathy or prophylaxis. The conditioning regimens used were BEAM (BCNU 300 mg/m cyclophosphamide 120 mg/kg) and CYTBI (TBI 14.4 Gy over 8 fractions, cyclophosphamide 120 mg/kg).
Twice weekly blood samples were collected from peripheral veins, the first 5 ml being discarded. The first sample was taken on day Ϫ7 or on admission and sampling was continued until the patient left the BMT unit. Samples were collected into 1 part citrate (0.11 mol/l) with 9 parts blood. Plasma was separated and stored at Ϫ70°C until assayed. The assays performed were thrombin-antithrombin complex (Enzygnost TAT micro; Behringwerke, Germany), prothrombin fragment F1ϩ2 (Enzygnost F1ϩ2 micro; Behringwerke, Germany), plasmin-␣2-antiplasmin (Enzygnost PAP micro; Behringwerke) and protein C (Coamatic Protein C; Chromogenix, Sweden). Serum albumin levels were estimated at least twice a week. Nutritional status was monitored by assessment of daily caloric and protein intake along with regular patient weight measurements.
Data were analysed on an intention to treat basis by either the Mann-Whitney test or two sample t-test to assess differences between the two groups.
Results
Eight patients withdrew from the trial, four each from both the glutamine and control groups. This was at the patient's request in all but one case, the patients complaining of nonspecific upper gastrointestinal symptoms with the sensation of abdominal fullness. One of the control group was withdrawn because of problems with the supply of the amino acid solution. One patient died during the initial BMT in patient stay. This patient, in the control group, died from sepsis and graft-versus-host disease. There were no cases of VOD.
The markers of thrombin generation (thrombinantithrombin (TAT) and prothrombin fragment F1ϩ2 (F1ϩ2) and plasmin generation (plasmin-␣2-antiplasmin (PAP) were unaffected by glutamine supplementation (Table 2) . Mean protein C and serum albumin levels were generally higher in patients receiving glutamine (Table 2 ). Significant differences between the two groups were observed during the early transplant period, protein C on days ϩ4 and ϩ7 (P Ͻ 0.05) and serum albumin on days 0 and ϩ4 (P Ͻ 0.02). The nutritional status of the patients in either group was not significantly different. Weight loss over the transplant period was similar between the two groups. Median weight loss was 6.7% (range 4.3-8.3%) and 7.4% (range 4-10%) for the glutamine (n = 16) and placebo (n = 15) groups, respectively, P = 0.72. Daily caloric (P Ͻ 0.1) and protein (P Ͼ 0.1) intake between admission and day ϩ14 were not significantly different, 1921 kcal (range 1031-3473 kcal) vs 1226 kcal (range 867-2249 kcal) and 59.5 g (range 26.1-128.9 g) vs 40 g (range 27.7-67.5 g), respectively, for the glutamine (n = 9) and placebo (n = 9) groups. One patient in the glutamine group was hepatitis C antibody positive with normal liver function tests. All other patients were negative for hepatitis B and C. Only one patient, in the control group, had a raised aspartate transaminase level on admission (55 IU/l) with no evidence of hepatitis B or C infection.
Discussion
Glutamine supplementation led to a preservation of protein C and albumin levels early in the post-transplant period. The effect on protein C is noteworthy as eight of the 18 patients in the glutamine group received warfarin and no subsequent vitamin K as compared to only one of the 16 patients in the control group. In these nine patients the unopposed action of warfarin during conditioning would have resulted in lower than expected protein C levels, ie favouring higher levels in the control group. These changes occurred without significant differences in the caloric and protein intake between the two groups. GSH depletion results from the chemotherapy used for conditioning. The observed differences in these markers of hepatic synthesis, soon after conditioning is completed, fit with the proposed mechanism of action of glutamine in maintaining hepatic GSH levels.
Glutamine is not strictly an essential amino acid, but is considered to be conditionally essential in that endogenous production is adequate under normal conditions but becomes inadequate during severe catabolic illness. GSH is a tripeptide consisting of glutamate, cysteine and glycine. Not easily transported across cell membranes, it is synthesised in cell mitochondria and under catabolic stress following cytotoxic therapy glutamine appears to be the limiting amino acid in its production. Experimental evidence supports a role for GSH depletion in the pathogenesis of VOD. In a canine model of VOD, addition of a glutathione synthase inhibitor to a non-VOD inducing dose of l-phenylalanine mustard resulted in early VOD lesions and fatal gastrointestinal toxicity. 7 Mice pre-treated with glutathione monoethylesters were protected from the lethal effects of agents such as monocrotaline, BCNU and cyclophosphamide. 5 Also, glutamine supplemented nutrition has been shown to preserve hepatic GSH levels, protect the liver and improve survival in Wistar rats receiving toxic doses of acetaminophen. 6 Reductions in protein C and albumin levels post-BMT have been described previously along with falls in factor X and factor VII levels. [8] [9] [10] These reductions are thought to be due to hepatic dysfunction. The preservation of protein C and albumin levels in the glutamine-treated patients suggests that glutamine preserves hepatic synthetic function. The data from the TAT, F1ϩ2 and PAP levels mean there is no effect on thrombin or plasmin generation post BMT. As these alterations in haemostatic parameters may reflect perturbation of endothelial cells there is no indirect evidence of glutamine protecting the endothelium.
There are conflicting data concerning the relevance of low protein C levels during the transplant period. Several studies have shown that low levels either prior to or during transplantation are predictive of VOD. 8, 9 The studies which showed this correlation tended to have higher levels of VOD than other groups. 8, 11 Protein C may therefore have significance in high-risk groups. Low protein C levels may be significant due to the development of a prothrombotic state. However, it has also been shown that low levels of factor VII prior to BMT are predictive of VOD despite the anticoagulant effect. 12 Other markers of hepatic dysfunction such as bilirubin, psuedocholinesterase and type III procollagen levels are also associated with the development of VOD. [12] [13] [14] Our preliminary data suggest that glutamine infusions during BMT preserve hepatic function. The likely mechanism of action is the maintenance of hepatic GSH levels, thus protecting hepatocytes from the oxidant stress of highdose conditioning regimens. Such antioxidant effects may prevent the development of severe VOD following chemoradiotherapy. Further studies with patients at high-risk of developing VOD seem indicated to investigate this potential therapeutic role of glutamine.
